

Table 1.19

Lifetime Risk (Percent) of Dying from Cancer by Site and Race/Ethnicity
Females, Total U.S., 2016-2018

| Site | All Races | Whites | Blacks |
|----------------------------------|------------------------|------------------------|------------------------|
| | Percent (95% C.I.) | Percent (95% C.I.) | Percent (95% C.I.) |
| All Sites | 17.88 (17.84, 17.91) | 18.04 (18.00, 18.08) | 17.90 (17.79, 18.01) |
| Oral Cavity and Pharynx | 0.19 (0.18, 0.19) | 0.19 (0.19, 0.20) | 0.14 (0.13, 0.15) |
| Esophagus | 0.19 (0.19, 0.20) | 0.20 (0.19, 0.20) | 0.19 (0.17, 0.20) |
| Stomach | 0.28 (0.28, 0.29) | 0.25 (0.24, 0.25) | 0.45 (0.43, 0.47) |
| Colon and Rectum | 1.61 (1.60, 1.62) | 1.59 (1.57, 1.60) | 1.82 (1.78, 1.86) |
| Liver and Intrahepatic Bile Duct | 0.55 (0.54, 0.56) | 0.52 (0.52, 0.53) | 0.59 (0.56, 0.61) |
| Pancreas | 1.37 (1.35, 1.38) | 1.35 (1.34, 1.36) | 1.51 (1.48, 1.55) |
| Larynx | 0.04 (0.04, 0.05) | 0.04 (0.04, 0.05) | 0.07 (0.06, 0.07) |
| Lung and Bronchus | 4.18 (4.16, 4.20) | 4.35 (4.33, 4.37) | 3.49 (3.44, 3.54) |
| Melanoma of the Skin | 0.18 (0.17, 0.18) | 0.20 (0.20, 0.21) | 0.04 (0.03, 0.04) |
| Breast | 2.54 (2.53, 2.56) | 2.50 (2.49, 2.52) | 3.04 (3.00, 3.09) |
| Cervix Uteri | 0.22 (0.21, 0.22) | 0.21 (0.20, 0.21) | 0.32 (0.30, 0.33) |
| Corpus and Uterus, NOS | 0.65 (0.64, 0.66) | 0.61 (0.60, 0.61) | 1.03 (1.00, 1.06) |
| Ovary | 0.84 (0.83, 0.85) | 0.88 (0.87, 0.89) | 0.66 (0.64, 0.69) |
| Urinary Bladder | 0.34 (0.34, 0.35) | 0.35 (0.34, 0.35) | 0.34 (0.32, 0.36) |
| Kidney and Renal Pelvis | 0.32 (0.32, 0.33) | 0.33 (0.33, 0.34) | 0.27 (0.26, 0.29) |
| Brain and Other Nervous System | 0.42 (0.41, 0.42) | 0.46 (0.45, 0.46) | 0.24 (0.23, 0.25) |
| Thyroid | 0.07 (0.07, 0.07) | 0.07 (0.07, 0.07) | 0.06 (0.06, 0.07) |
| Hodgkin Lymphoma | 0.03 (0.03, 0.03) | 0.03 (0.03, 0.03) | 0.02 (0.01, 0.02) |
| Non-Hodgkin Lymphoma | 0.61 (0.60, 0.62) | 0.64 (0.63, 0.65) | 0.36 (0.35, 0.38) |
| Myeloma | 0.37 (0.36, 0.37) | 0.34 (0.33, 0.34) | 0.64 (0.62, 0.67) |
| Leukemia | 0.67 (0.66, 0.68) | 0.69 (0.68, 0.70) | 0.54 (0.52, 0.56) |
| Acute Lymphocytic Leukemia | 0.04 (0.04, 0.04) | 0.04 (0.04, 0.04) | 0.03 (0.03, 0.04) |
| Chronic Lymphocytic Leukemia | 0.14 (0.13, 0.14) | 0.14 (0.14, 0.15) | 0.11 (0.10, 0.12) |
| Acute Myeloid Leukemia | 0.29 (0.28, 0.29) | 0.30 (0.29, 0.30) | 0.22 (0.21, 0.24) |
| Chronic Myeloid Leukemia | 0.04 (0.03, 0.04) | 0.04 (0.03, 0.04) | 0.03 (0.03, 0.04) |

Devcan Version 6.7.9, April 2021s, National Cancer Institute (<https://surveillance.cancer.gov/devcan/>).
Source: NCHS public use data file for the total US.
A percent or confidence interval value of 0.00 represents a value that is below 0.005.

Table 1.19 - continued

Lifetime Risk (Percent) of Dying from Cancer by Site and Race/Ethnicity
Females, Total U.S., 2016-2018

| Site | Asian/Pacific Islanders | American Indian/ Alaska Natives ^a | Hispanics ^b |
|----------------------------------|----------------------------|---|------------------------|
| | Percent (95% C.I.) | Percent (95% C.I.) | Percent (95% C.I.) |
| All Sites | 15.69 (15.46, 15.94) | 15.02 (14.44, 15.64) | 15.38 (15.23, 15.53) |
| Oral Cavity and Pharynx | 0.21 (0.18, 0.24) | 0.15 (0.08, 0.28) | 0.14 (0.12, 0.16) |
| Esophagus | 0.15 (0.12, 0.18) | 0.18 (0.12, 0.30) | 0.12 (0.10, 0.13) |
| Stomach | 0.78 (0.72, 0.84) | 0.44 (0.35, 0.58) | 0.61 (0.58, 0.65) |
| Colon and Rectum | 1.63 (1.55, 1.72) | 1.70 (1.48, 1.96) | 1.52 (1.47, 1.58) |
| Liver and Intrahepatic Bile Duct | 1.00 (0.94, 1.07) | 0.86 (0.73, 1.03) | 1.01 (0.97, 1.05) |
| Pancreas | 1.38 (1.31, 1.46) | 0.98 (0.83, 1.18) | 1.39 (1.34, 1.44) |
| Larynx | 0.02 (0.01, 0.04) | 0.03 (0.01, 0.12) | 0.02 (0.02, 0.03) |
| Lung and Bronchus | 3.11 (3.00, 3.22) | 3.36 (3.08, 3.68) | 2.04 (1.98, 2.10) |
| Melanoma of the Skin | 0.06 (0.04, 0.09) | 0.06 (0.03, 0.16) | 0.08 (0.07, 0.09) |
| Breast | 1.83 (1.75, 1.92) | 1.85 (1.64, 2.10) | 2.02 (1.97, 2.08) |
| Cervix Uteri | 0.22 (0.20, 0.25) | 0.21 (0.16, 0.32) | 0.29 (0.27, 0.30) |
| Corpus and Uterus, NOS | 0.52 (0.48, 0.56) | 0.40 (0.32, 0.53) | 0.61 (0.58, 0.64) |
| Ovary | 0.66 (0.62, 0.71) | 0.67 (0.56, 0.83) | 0.72 (0.69, 0.75) |
| Urinary Bladder | 0.25 (0.21, 0.30) | 0.27 (0.17, 0.43) | 0.27 (0.25, 0.30) |
| Kidney and Renal Pelvis | 0.20 (0.17, 0.24) | 0.45 (0.34, 0.62) | 0.37 (0.35, 0.40) |
| Brain and Other Nervous System | 0.28 (0.25, 0.31) | 0.25 (0.18, 0.37) | 0.37 (0.35, 0.40) |
| Thyroid | 0.14 (0.11, 0.17) | 0.07 (0.02, 0.20) | 0.13 (0.11, 0.14) |
| Hodgkin Lymphoma | 0.02 (0.01, 0.03) | 0.03 (0.01, 0.13) | 0.05 (0.04, 0.06) |
| Non-Hodgkin Lymphoma | 0.60 (0.55, 0.66) | 0.41 (0.31, 0.56) | 0.66 (0.63, 0.70) |
| Myeloma | 0.26 (0.23, 0.30) | 0.43 (0.32, 0.60) | 0.37 (0.35, 0.40) |
| Leukemia | 0.49 (0.44, 0.54) | 0.32 (0.24, 0.46) | 0.58 (0.55, 0.61) |
| Acute Lymphocytic Leukemia | 0.04 (0.03, 0.06) | 0.04 (0.02, 0.13) | 0.06 (0.06, 0.07) |
| Chronic Lymphocytic Leukemia | 0.04 (0.03, 0.06) | 0.01 (0.00, 0.11) | 0.07 (0.06, 0.09) |
| Acute Myeloid Leukemia | 0.26 (0.24, 0.30) | 0.16 (0.11, 0.28) | 0.24 (0.23, 0.26) |
| Chronic Myeloid Leukemia | 0.02 (0.01, 0.04) | 0.02 (0.01, 0.12) | 0.02 (0.02, 0.03) |

Devcan Version 6.7.9, April 2021s, National Cancer Institute (<https://surveillance.cancer.gov/devcan/>).

Source: NCHS public use data file for the total US.

^a Underlying mortality data for American Indian/Alaska Native are based on the PRCDAs (Purchased/Referred Care Delivery Areas) counties.

^b Hispanic is not mutually exclusive from whites, blacks, Asian Pacific Islanders, and American Indians/Alaska Natives.
A percent or confidence interval value of 0.00 represents a value that is below 0.005.